ThermoDox heat-activated liposome: Interim Phase II data

Interim data from 12 evaluable patients with recurrent chest wall breast cancer in the Phase II portion of the open-label U.S. Phase I/II DIGNITY trial showed that 50 mg/m 2 ThermoDox plus mild local hyperthermia produced a local response rate of 58%, including 5 complete responses and 2 partial responses, plus 1 case of stable disease. In 3Q15, Celsion expects to complete enrollment of up to 20 patients in the trial. The company has previously reported interim data from the trial (see BioCentury, Oct. 15, 2012 & March 10, 2014). This quarter, Celsion plans to start the European Euro-DIGNITY trial of ThermoDox in patients with recurrent chest wall breast cancer. ...